Commit Biologics
Mikkel Wandahl Pedersen is an accomplished biotechnology professional with extensive experience in leadership roles within the scientific community. Currently serving as the Chief Scientific Officer at Commit Biologics since October 2024, Mikkel has previously held the position of CEO and co-founder at Analona Therapeutics from June 2024 to September 2024, and served as Chief Scientific Officer at Nykode Therapeutics from 2021 to 2024. Prior roles include Head of Biologics Drug Design at Servier and multiple senior positions at Symphogen, where Mikkel contributed to antibody discovery and research over a span of 15 years. Mikkel's academic background includes a PhD in Cancer from the University of Copenhagen and a Master's degree in Human Biology, with significant contributions to the fields of cancer biology and immunology, including a notable history of publishing and presenting scientific research.
This person is not in any teams
This person is not in any offices
Commit Biologics
Commit Biologics (Commit) is a pioneer in activating the complement system to kill specific target cells, with applications in cancers and autoimmune diseases. Spun out of Aarhus University, and building on more than three decades of research, Commit’s Bispecific Complement Engaging (BiCE™) platform can supercharge a conventional monoclonal antibody to activate the complement system more effectively. This is achieved by combining single domain antibodies that engage C1q, the starting point for the complement activation cascade, with an antibody that binds to a cellular target. The modular approach of the BiCE™ technology can be used to develop therapeutics across multiple tumor-associated antigens and immune cell targets. Complement is a largely untapped aspect of the body’s natural immune system that leverages both the direct cytolytic activity of complement along with its ability to bridge recruitment and activation of both innate and adaptive immune cells – a new approach to killing cells which can be used in combination or on a standalone basis. Commit is backed by major investors including Bioqube Ventures and Novo Holdings, as well as initial funding from the Bio Innovation Institute from Denmark.